retatrutide availability south africa Extreme Side Effects Followed Overdose of Unapproved Weight-Loss Drug Efficacy of GLP-1 analog peptides,

Cyano has cyanide in which can effect some people

GLP-1 Receptor Agonist Market Segmentation Analysis By Product By product, the semaglutide segment accounted for a share of 51.23% in 2025, owing to its broad regulatory approvals across type 2 diabetes and obesity and proven cardiovascular risk reduction benefits

Liraglutide (Saxenda) was approved for chronic weight management in 2014, but semaglutide (Wegovy) in June 2021 marked the turning pointoffering weekly dosing and superior weight loss outcomes that transformed public awareness

When comparisons were made with other oral drugs used in type 2 diabetes, the reductions in HbA 1c were comparable with glitazones, but slightly less than with metformin or sulphonylureas